<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04216459</url>
  </required_header>
  <id_info>
    <org_study_id>high risk of sepsis</org_study_id>
    <nct_id>NCT04216459</nct_id>
  </id_info>
  <brief_title>Effect of Anti-inflammatory and Anti-microbial Co-supplementations in Traumatic ICU Patients at High Risk of Sepsis</brief_title>
  <acronym>DrNoha-ICU</acronym>
  <official_title>Effect of Anti-inflammatory and Anti-microbial Co-supplementations in Traumatic ICU Patients at High Risk of Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The occurrence of sepsis in trauma patients is a very serious complication. Identifying&#xD;
      trauma patients at high risk of sepsis was not revealed in the latest surviving sepsis&#xD;
      campaign in 2016. Several biomarkers have been proposed for early prediction of sepsis in&#xD;
      trauma patients as leukocyte anti sedimentation rate (LAR) and the proinflammatory cytokine&#xD;
      monocyte chemo attractant protein-1 (MCP-1). Sepsis prophylaxis before occurrence of&#xD;
      multi-organ failure still represents a major challenge. Vitamin D and probiotics have&#xD;
      antimicrobial, anti-inflammatory and gut microbiota immune modulatory properties.Little is&#xD;
      known about the effect of vitamin D and probiotics co-supplementation on the inflammatory&#xD;
      response in trauma patients at high risk of sepsis.&#xD;
&#xD;
      Another promising strategy is the use of vitamin C in addition to thiamine. Trauma is&#xD;
      associated with increased oxidative stress and vitamin C deficiency. High dose vitamin C is&#xD;
      required to restore oxidant-antioxidant balance. Vitamin C and thiamine have shown promising&#xD;
      results in treatment of sepsis. Vitamin C possesses anti-inflammatory, endothelial protective&#xD;
      and anti-microbial effects. Thiamine is the precursor of thiamine pyrophosphate (TPP), a key&#xD;
      enzyme in Krebs cycle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate effect of vitamin D and probiotics versus Vitamin C and thiamine&#xD;
      on inflammatory response (represented by change in MCP-1 level), Sequential Organ Failure&#xD;
      Assessment (SOFA) Score and Acute Physiology and Chronic Health Evaluation II (APACHE II) in&#xD;
      trauma patients at high risk of sepsis. Secondary goal is to assess if the predictive ability&#xD;
      of MCP-1 plus LAR to determine high risk of sepsis in major trauma intensive care patients&#xD;
      and if there is correlation between LAR and MCP-1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 18, 2020</start_date>
  <completion_date type="Actual">October 4, 2021</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Physiology and Chronic Health Evaluation II (APACHE II) score</measure>
    <time_frame>0n the Day 0-Day 6 from onset of trauma</time_frame>
    <description>minim 0 maximum 71 Increasing score is associated with increasing risk of ICU mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) score</measure>
    <time_frame>0n the Day 0-Day 6 from onset of trauma</time_frame>
    <description>minim 0 maximum 24 The acute increase of 2 or more in SOFA points indicates sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocyte chemo attractant protein 1 (MCP-1)</measure>
    <time_frame>0n the Day 0-Day 6 from onset of trauma</time_frame>
    <description>Optimum cut-off value of MCP-1 for prediction of sepsis in severe trauma ICU patients is 240.7 pg/ml The decrease in its level indicates less inflammatory response and better patient out comes</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Major Trauma</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Low risk group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no specific treatment will be given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High risk control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no specific treatment will be given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High risk DP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive one intramuscular (IM) injection of 400,000 IU of cholecalciferol on day- 1 Also, starting from day 1 and till day 6 (for consequential 6 days), patients will receive lactobacillus probiotics (10 billion colony forming unit) in a dose of 6 sachets per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High risk CB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive vitamin C plus thiamine starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral lactobacillus probiotics plus intramuscular cholecalciferol</intervention_name>
    <description>According to leukocyte anti- sedimentation rate (LAR) result on day 1 patients will be classified into high risk for sepsis patients (LAR &lt; 15 %) and low risk for sepsis patients (LAR ≥ 15%) High risk sepsis patients will be randomly allocated into one of the 3 groups (sealed opaque envelops) to vitamin D plus probiotics intervention group (HR-DP) group. to vitamin C plus vitamin B intervention group (HR-CB) group. to control group (HR-C) group that does not receive any supplement</description>
    <arm_group_label>High risk DP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous vitamin C plus thiamine</intervention_name>
    <description>starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours</description>
    <arm_group_label>High risk CB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult trauma patients admitted to ICU within 24 hours from trauma onset with injury&#xD;
             severity score (ISS) ≥ 16 will be recruited after obtaining informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Patients admitted to ICU after time exceeding 24 hours from trauma onset.&#xD;
&#xD;
               -  Patients whose age is less than 18 years.&#xD;
&#xD;
               -  Pregnant female.&#xD;
&#xD;
               -  Breast feeding women.&#xD;
&#xD;
               -  Arrest within 24 hours of admission.&#xD;
&#xD;
               -  Immune deficiency or administration of immune suppressant drugs.&#xD;
&#xD;
               -  Serum calcium greater than or equal to 10 mg/dl or phosphate greater than or&#xD;
                  equal 6 mg/dl.&#xD;
&#xD;
               -  History of primary parathyroid disease.&#xD;
&#xD;
               -  Metabolic bone disease.&#xD;
&#xD;
               -  Sarcoidosis.&#xD;
&#xD;
               -  End stage renal disease.&#xD;
&#xD;
               -  receiving intermittent renal replacement therapy (RRT).&#xD;
&#xD;
               -  Failure of enteral feeding or any contraindication to enteral administration.&#xD;
&#xD;
               -  Obesity , body mass index (BMI &gt; 35 kg/m2)&#xD;
&#xD;
               -  Known contraindication to vitamin C or thiamine (oxalate nephropathy or known&#xD;
                  glucose-6-phosphate dehydrogenase deficiency)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maha Ahmed Abozeid, MD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine - Mansoura University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mansoura University-Emergency hospital-ICU</name>
      <address>
        <city>Mansoura</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 30, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>maha abou-zeid</investigator_full_name>
    <investigator_title>lecturer of Anesthesia and Surgical Intensive Care</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Thiamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

